Norbert G. Riedel, Ph.D., is corporate vice president and chief scientific officer at Baxter International Inc., having served in that capacity since March 2001. Before assuming this role, Dr. Riedel served as president of the recombinant proteins business unit and vice president of research and development within Baxter's BioScience business. Prior to joining Baxter in 1998, he was head of worldwide biotechnology and worldwide core research functions at Hoechst Marion Roussel, now Sanofi-Aventis.
Dr. Riedel serves on the board of directors of Oscient Pharmaceuticals Corporation and Medigene AG. He is chairman of the Illinois Biotechnology Industry Organization and a member of the Advisory Board of Northwestern University's Kellogg School of Management Center for Biotechnology.
Dr. Riedel received his Ph.D. in biochemistry from the University of Frankfurt in 1983. He was a postdoctoral fellow at Harvard University from 1984 to 1987, assistant professor and associate professor of medicine and biochemistry at Boston University School of Medicine from 1987 to 1991, and a visiting professor at Massachusetts Institute of Technology in 1992. He remains affiliated with Boston University as an adjunct professor and also serves as an adjunct professor of medicine at Northwestern University's Feinberg School of Medicine.
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.
Print this page
